| |
Key
Challenges in Biocontainment BSL-3 Lab Design
Nicholas A. Caronna,
PE, CRB Consulting Engineers, Inc.
Objectives:
Challenges and strategies in the design and operation of a Biocontainment
BSL-3 Lab have become increasingly apparent in the wake of current
events. Biodefense initiatives by the NIAID and the private sector
present new challenges in this specialty lab design. Basic principles
of biological containment will be presented. There will be a brief
discussion of:
- Biocontainment classifications
- Containment Barrier types
- Design methodologies
- Sample Layouts
- Vaccine research trends
- Codes and Standards
- Benchmark capital and operating cost parameters
- Community Response and Perceptions
This presentation will discuss the relationship between the owners
need for control of first cost, the facility managers need to control
safety and operating cost, and the designers responsibility for
health, safety and welfare. All of these decisions must be managed
to balance the needs against the return on investment. Attendees
will learn the pros/cons as well the reality of making educated
laboratory decisions.
Findings:
Basic principles of biological containment will be presented. This
presentation will discuss the relationship between the owners need
for control of first cost, the facility managers need to control
safety and operating cost and the designers responsibility for health
safety and welfare. All of these decisions must be managed to balance
the needs against the return on investment.
Labs21 Connection:
Attendees will learn the pros/cons as well the reality of making
educated laboratory decisions.
Biography:
Nicholas A. Caronna, PE, is a licensed
Mechanical Engineer in 10 states with over 22 years experience in
programming and designing laboratories and challenging high-tech
industrial and biopharm facilities for private and public sector
clients. He has been involved in the design of over 1.2 Million
SF of lab space. He has a B.S. degree in Mechanical Engineering
from Syracuse University and is a member of ISPE, ASHRAE, and AFE.
As a Senior Project Manager and Associate with Clark, Richardson
& Biskup Consulting Engineers, Inc. ("CRB"), he is
also the PharmaTech Team Leader, responsible for the pharmaceutical,
laboratory and high technology business sector for the Southeast.
He is the Labs21 Biocontainment Roundtable Leader, has presented
"Laboratory Flexibility and User Needs", at Labs21 on
October 7, 2002; "Green Lab Design", at Tradeline on May
1, 2001; and authored "Preventing Combustion in Hazardous-Area
Design" for Consulting-Specifying Engineer, May 1994.
He has recently served as Engineering Project Manager for:
- 1999 National Design/Build, Award-winning Eli Lilly/Sphinx Pharmaceutical
Laboratory Building, RTP, NC (1998/1999)
- Closure Medical Lab/Manuf. Facility, Raleigh, NC (1999)
- Amersham Pharmacia Laboratory, Piscataway, NJ (1999/2000)
- Paradigm Genetics Laboratory Facility, RTP, NC (2000)
- Biogen Bio-24 Laboratory Facility, RTP, NC (2001/2002)
- Duke University BSL-3 Laboratory, Durham, NC (2002)
- Confidential Client Vivarium BSL-3 Facility Study, Athens, GA
(2002)
- Confidential Client Laboratory Facility, Athens, GA (2002/2003)
- Biogen Pilot Plant, RTP, NC (2002 Design only)
- GlaxoSmithKline QC Laboratory Benchmark Study, Wavre, Belgium
(2003)
- Trimeris Analytical and QC Laboratory Facility, RTP, NC (2003
Design)
- Triangle Life Sciences Center Laboratory Facility, RTP, NC (2003/2004
Design) - formerly the EPA Research Center.
|
